株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

転移性乳癌:パイプライン分析

Metastatic Breast Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229722
出版日 ページ情報 英文 1096 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
転移性乳癌:パイプライン分析 Metastatic Breast Cancer - Pipeline Review, H2 2016
出版日: 2016年12月07日 ページ情報: 英文 1096 Pages
概要

転移性乳癌(ステージIV期または進行性)とは、癌細胞が乳房の腫瘍から転移して体の他の部位に広がり、増え続けている状態を指します。転移性乳癌の症状は、激痛、進行性の痛み、まれに病的な骨折、患部の骨の紅斑、腫れ、黄疸、肝酵素の上昇、腹痛、食欲不振、悪心、嘔吐などが見られます。治療には、ホルモン療法、化学療法、放射線療法、外科手術などが含まれます。

当レポートでは、転移性乳癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

転移性乳癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adgero Biopharmaceuticals, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Alteogen Inc.
  • Amarna Therapeutics B.V.
  • Ambrx, Inc.
  • Amgen Inc.
  • Aphios Corporation
  • arGEN-X BV
  • Aslan Pharmaceuticals Pte. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Beta Pharma, Inc.
  • Biocon Limited
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Campus Technologies Freiburg GmbH 他

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8794IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.

Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, and, less commonly, pathological fracture, erythema over the affected bone, swelling, jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting. Other symptoms include fatigue, malaise and weight loss. Treatment includes hormone therapy, chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1 molecules, respectively.Metastatic Breast Cancer.

Metastatic Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Breast Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Breast Cancer Overview
  • Therapeutics Development
  • Metastatic Breast Cancer - Therapeutics under Development by Companies
  • Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Breast Cancer - Pipeline Products Glance
  • Metastatic Breast Cancer - Products under Development by Companies
  • Metastatic Breast Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Breast Cancer - Companies Involved in Therapeutics Development
  • Metastatic Breast Cancer - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Breast Cancer - Dormant Projects
  • Metastatic Breast Cancer - Discontinued Products
  • Metastatic Breast Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Breast Cancer, H2 2016
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Breast Cancer - Pipeline by 3SBio Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by AB Science SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by AbbVie Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Advaxis Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Metastatic Breast Cancer - Pipeline by Alteogen Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016
  • Metastatic Breast Cancer - Pipeline by Ambrx Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Amgen Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Aphios Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Arvinas Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2016
  • Metastatic Breast Cancer - Pipeline by Beta Pharma Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Biocon Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Bionovis SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Metastatic Breast Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Celgene Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Celltrion Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Clovis Oncology Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2016
  • Metastatic Breast Cancer - Pipeline by Curaxys SL, H2 2016
  • Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H2 2016
  • Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici SpA, H2 2016
  • Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by EirGenix Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by EOS Biosciences Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Epigen Biosciences Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Etubics Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by FibroGen Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Genelux Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Genentech Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Gilead Sciences Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Metastatic Breast Cancer - Pipeline by GP Pharm SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by GTx Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Hetero Drugs Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Humorigin Biotechnology Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Immune Design Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Immunomedics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Immunophotonics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Immupharma Plc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Incyte Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Metastatic Breast Cancer - Pipeline by Kadmon Corp LLC, H2 2016
  • Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2016
  • Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by MacroGenics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by MandalMed Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Meabco A/S, H2 2016
  • Metastatic Breast Cancer - Pipeline by MedImmune LLC, H2 2016
  • Metastatic Breast Cancer - Pipeline by Medivation Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Merck & Co Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Merck KGaA, H2 2016
  • Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Merus NV, H2 2016
  • Metastatic Breast Cancer - Pipeline by MetaStat Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Morphotek Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by NantKwest Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Natco Pharma Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2016
  • Metastatic Breast Cancer - Pipeline by Neonc Technologies Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by NewLink Genetics Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2016
  • Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016
  • Metastatic Breast Cancer - Pipeline by OBI Pharma Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Oncobiologics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
  • Metastatic Breast Cancer - Pipeline by Pfizer Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Pharma Mar SA, H2 2016
  • Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H2 2016
  • Metastatic Breast Cancer - Pipeline by Plexxikon Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Polyphor Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Puma Biotechnology Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Radius Health Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016
  • Metastatic Breast Cancer - Pipeline by Samyang Holdings Corp, H2 2016
  • Metastatic Breast Cancer - Pipeline by Sanofi, H2 2016
  • Metastatic Breast Cancer - Pipeline by Seattle Genetics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H2 2016
  • Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Tocagen Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Tyme Technologies Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016
  • Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Vyriad Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2016
  • Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2016
  • Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Metastatic Breast Cancer - Pipeline by Zymeworks Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Breast Cancer - Dormant Projects, H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..9), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..10), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..11), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..12), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..13), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..14), H2 2016
  • Metastatic Breast Cancer - Dormant Projects (Contd..15), H2 2016
  • Metastatic Breast Cancer - Discontinued Products, H2 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..4), H2 2016
  • Metastatic Breast Cancer - Discontinued Products (Contd..5), H2 2016

List of Figures

  • Number of Products under Development for Metastatic Breast Cancer, H2 2016
  • Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top